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Foxp3+ T regulatory (Treg) cells regulate immune re-
sponses and maintain self-tolerance. Recent work
shows that Tregcells are comprisedofmany subpop-
ulations with specialized regulatory functions. Here
we identified Foxp3+ T cells expressing the coinhi-
bitory molecule TIGIT as a distinct Treg cell subset
that specifically suppresses proinflammatory T help-
er 1 (Th1) and Th17 cell, but not Th2 cell responses.
Transcriptional profiling characterized TIGIT+ Treg
cells as an activated Treg cell subset with high
expression of Treg signature genes. Ligation of TIGIT
on Treg cells induced expression of the effector
molecule fibrinogen-like protein 2 (Fgl2), which pro-
moted Treg-cell-mediated suppression of T effector
cell proliferation. In addition, Fgl2 was necessary to
prevent suppression of Th2 cytokine production in a
model of allergic airway inflammation. TIGIT expres-
sion therefore identifies a Treg cell subset that
demonstrates selectivity for suppression of Th1 and
Th17 cell but not Th2 cell responses.
INTRODUCTION
Regulatory T cells (Treg cells) are a subset of CD4+ T cells that
are marked by expression of the transcription factor Foxp3
and act as a central component in regulating immune responses
to pathogens and in maintaining self-tolerance. Other regulatory
populations also contribute to this balance, but Foxp3+ Treg
cells are critical for maintaining immune homeostasis as demon-
strated by the devastating multiorgan autoimmune disease
caused by genetic deficiencies in Foxp3 (Brunkow et al., 2001;
Wildin et al., 2001). A series of recent reports has led to the
emerging concept that Foxp3+ Treg cells are not all identical,
but rather are comprised of multiple, functionally diverse sub-types with distinct phenotypes and specialized functions.
Foxp3+ Treg cells have been shown to specialize to selectively
regulate specific effector T cell responses and control inflamma-
tion at defined anatomical tissue sites (Chaudhry et al., 2009;
Cipolletta et al., 2012; Koch et al., 2009; Zheng et al., 2009).
Although the transcription factors that differentially induce
specialized suppressor functions in Treg cells have been identi-
fied, the molecules that mediate these selective effector func-
tions remain largely unknown. Identification of cytokines and
cell surface molecules that mediate specialization of Treg
cell function would allow the development of therapeutic
approaches that target Treg cells to selectively regulate specific
types of T cell responses.
In conventional T cells, cytokines and costimulatory mole-
cules act in concert to control differentiation and acquisition of
effector functions. For example, OX40 (CD134) augments Th2
cell responses and, by increasing IL-4 secretion, favors the in-
duction of Th9 cells (Flynn et al., 1998; Xiao et al., 2012). Simi-
larly, inducible costimulator (ICOS) regulates T follicular helper
(Tfh) cell expansion and critically contributes to Th17 cell func-
tion by regulating IL-23 receptor expression in an IL-21- and
c-Maf-dependent manner (Bauquet et al., 2009). In Treg cells,
coinhibitory molecules, such as programmed cell death 1
(PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), promote
suppressive function. PD-1 plays an important role in iTreg cell
stability and suppressive function (Francisco et al., 2009).
CTLA-4 is essential for Treg cell function (Wing et al., 2008)
and can mediate suppression by enabling Treg cells to compete
with effector T cells for costimulatory signals on APCs and by in-
ducing the production of indoleamine 2,3-dioxygenase (IDO) in
APCs, thereby limiting T cell proliferation (Fallarino et al., 2003).
Although costimulatory molecules have been shown to promote
effector functions of defined T helper cell lineages, there are
no reports that implicate coinhibitory molecules in the special-
ized function of Treg cell subsets, despite their important role
in promoting the suppressive function of Treg cells in general.
Recently, the coinhibitory molecule TIGIT has gained attention
as an inhibitor of autoimmune responses (Joller et al., 2011;
Levin et al., 2011). TIGIT can inhibit T cell responses by bindingImmunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 569
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TIGIT+ Treg Cells Suppress Proinflammatory Responsesthe ligand CD155 onDCs and thereby inhibit IL-12while inducing
IL-10 production (Yu et al., 2009). In addition, TIGIT engagement
directly inhibits T cell activation and proliferation (Joller et al.,
2011; Levin et al., 2011; Lozano et al., 2012). Like other coin-
hibitory molecules, TIGIT is highly expressed on Treg cells (Levin
et al., 2011; Yu et al., 2009); however, whether it plays a func-
tional role in these cells has not been explored.
In this study we examined the role of TIGIT on Treg cells. Our
results show that TIGIT expression defines a functionally distinct
Treg cell subset with an activated phenotype. TIGIT not only acts
as a marker for this Treg cell subset but also contributes to the
selective Treg-cell-mediated suppression of proinflammatory
Th1 and Th17 cells but not Th2 cell responses by inducing the
secretion of the soluble effector molecule fibrinogen-like protein
2 (Fgl2).
RESULTS
TIGIT Expression on Treg Cells Defines a Functionally
Distinct Treg Cell Subset
Previous reports have shown that TIGIT is expressed on Treg
cells (Levin et al., 2011; Yu et al., 2009). We first tested whether
TIGIT was expressed in natural as well as in vitro differentiated
induced Treg cells (nTreg and iTreg cells, respectively) and de-
tected expression of TIGIT on both Treg cell populations (Fig-
ure 1A). To address whether TIGIT functionally contributes to
Treg cell differentiation, we tested the ability of TIGIT-deficient
T cells to differentiate into Foxp3+ iTreg cells in vitro. Indeed,
TIGIT-deficient T cells generated a lower frequency of Foxp3+
T cells after 4 days of TGF-b-mediated differentiation (Figure 1B).
Conversely, transgenic overexpression of TIGIT led to the gene-
ration of a greater frequency of iTreg cells, confirming that TIGIT
promotes iTreg cell differentiation (Figure 1C). Because iTreg
cells expressed high amounts of TIGIT, we askedwhether TIGIT+
Treg cells present in vivo might also be generated peripherally.
However, TIGIT+ Treg cells were primarily Neuropilin-1+ and
expressed high amounts of Helios, indicating that the majority
of TIGIT+ Treg cells are nTreg cells (Figures S1A and S1B avail-
able online). In addition, TIGIT+ Treg cells do not appear to
be a terminally differentiated lineage because both TIGIT+ and
TIGIT Treg cells can convert into the other subset, as evidenced
by the loss of TIGIT from TIGIT+ Treg cells upon adoptive
transfer and conversely gain of TIGIT expression in transferred
TIGIT Treg cells. However, the vast majority of TIGIT+ Treg cells
maintain their TIGIT+ phenotype (Figure S1C).
We then tested whether TIGIT+ and TIGIT Treg cells also
display functional differences by comparing their ability to
suppress CD4+Foxp3 effector T cells in vitro. TIGIT+ nTreg cells
showed an increased ability to suppress TCR-stimulated pro-
liferation of conventional T cells (Figure 1D). TIGIT therefore
marks a functionally distinct subset of nTreg cells with superior
suppressive capacity in vitro.
Next, we determined whether TIGIT+ Treg cells are also de-
tected in humans and whether they might represent a similarly
potent Treg cell subset as in mice. We first analyzed TIGIT
expression in human CD4+ T cells and found that a large propor-
tion of human Treg cells are TIGIT+ (Figure 1E). We then per-
formed in vitro suppression assays to test whether human TIGIT+
and TIGIT Treg cells also differ in their suppressive capacity.570 Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc.Indeed, we detected increased suppression by TIGIT+ Treg cells
compared to TIGIT Treg cells (Figures 1F–1H), indicating that
TIGIT+ Treg cells are highly suppressive and may represent a
functionally distinct Treg cell subset in humans.
TIGIT+ Treg Cells Display an Activated Phenotype
To better understand the differences between TIGIT+ and TIGIT
Treg cells, we analyzed their gene expression patterns by micro-
array profiling. Overall, a total of 472 and 184 genes were over- or
underexpressed in TIGIT+ Treg cells relative to their TIGIT coun-
terparts (with an arbitrary cut-off of at fold change > 2 and t test
p < 0.05; Figure S1D, Table S1). These belonged to several
functional families including chemokines/cytokines or their re-
ceptors, transcription factors, and costimulatory and other
surface receptors, as well as molecules typical of Treg cells.
Overall, TIGIT+ Treg cells seemed to display a more activated
phenotype than their TIGIT counterparts (Figures S1E and
S1F). Furthermore, TIGIT+ Treg cells expressed 3-fold higher
levels of Ki67 and incorporated four times higher amounts of
BrdU than their TIGIT counterparts when we labeled prolifer-
ating cells in vivo (Figures S1G and S1H). The activated pheno-
type of TIGIT+ Treg cells observed by transcriptional profiling
therefore translates into a higher rate of proliferation in vivo.
TIGIT+ Treg Cells Share Features with Proinflammatory
T Cell Lineages
Treg cells share a number of features with the effector popu-
lation they suppress, including the expression of chemokine
receptors as well as the transcription factors that induce the
development of those effector T cells (Chaudhry et al., 2009;
Chung et al., 2011; Koch et al., 2009; Linterman et al., 2011;
Zheng et al., 2009). The pattern of chemokine receptors ex-
pressed by TIGIT+ Treg cells does not overlap with that of
any particular Th effector cell subset (Figure 2A), but includes
receptors that are expressed by several lineages, mainly by
the proinflammatory Th1 and Th17 cell subsets (Ccr2, Ccr5,
Ccr6, Cxcr3, and Cxcr6), but to a lesser degree also those ex-
pressed by Th2 (Ccr3) or Tfh (Cxcr5) cells. This might indicate
that TIGIT+ Treg cells are equipped to target a broad spectrum
of effector cells and tissues, specifically under proinflammatory
conditions.
Similarly, the transcription factors that are more highly ex-
pressed in TIGIT+ Treg cells do not specifically fall within the
fingerprint of a particular effector lineage (Figure 2B). Transcrip-
tion factors that are expressed in higher amounts by TIGIT+ Treg
cells include those that are specific for Th1 (Tbx21) and Th17
cells (Rora, Rorc, Irf4, Ahr), whereas only minor or no differences
could be observed in the expression of the Th2-cell-lineage
factor Gata3 and the Tfh-cell-lineage-specific transcription
factor Bcl6 (Figure 2C). Prdm1, a transcription factor that
transactivates IL-10 expression (Cretney et al., 2011), was ex-
pressed in higher amounts in TIGIT+ Treg cells, consistent with
increased production of IL-10 by these cells (Figures 2A, 2C,
and S2A).
We analyzed the expression profile of TIGIT+ Treg cells in rela-
tion to signatures of previously described Treg cell subsets.
TIGIT+ Treg cells were enriched for a gene set that distinguishes
CXCR3+ Treg cells: cells that express T-bet and were shown to
be specialized in suppression of Th1 cell responses (Figure 2D;
Figure 1. TIGIT Is Expressed on Highly Suppressive Treg Cells and Promotes iTreg Cell Differentiation
(A) CD4+ T cells were purified from Foxp3-GFP.KI mice and the Foxp3+ and Foxp3 cells were sorted. Foxp3+ nTreg cells were stained directly for TIGIT (solid line)
or with an isotype control (dotted line) and analyzed by flow cytometry. Foxp3+ induced Treg (iTreg) cells were analyzed after 4 days of stimulation with TGF-b.
(B and C) Naive CD4+CD62L+ T cells were sorted from WT, Tigit/ (B), or Tigit tg (C) mice and differentiated as in (A). Foxp3 expression was analyzed by flow
cytometry (mean ± SD).
(D) CD4+Foxp3+TIGIT+ (closed diamond) or CD4+Foxp3+TIGIT (open diamond) Treg cells were sorted from Foxp3-GFP.KI mice and titrated onto Foxp3GFP
effector T cells stimulated with anti-CD3 and APCs. Proliferation was measured after 72 hr by 3H-thymidine incorporation. Mean ± SD; *p < 0.01; representative
experiment of >10 independent experiments.
(E) Sorting strategy of ex vivo FACS-sorted human effector T cells (CD4+CD25+CD127+) and Treg cells (CD4+CD25hiCD127) sorted into TIGIT+ and TIGIT.
(F) Treg cells sorted as outlined in (E) showed >96% purity in both subsets measured by Foxp3 staining after isolation.
(G) Representative suppression assaywith humanCD4+CD25hiCD127TIGIT+ and TIGIT Treg cells cocultured with CFSE-labeled CD25-depleted CD4+ effector
T cells for 4 days.
(H) Statistical summary of (G) of six healthy donors (mean ± SEM; *p < 0.05).
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TIGIT+ Treg Cells Suppress Proinflammatory ResponsesKoch et al., 2009, 2012). IRF4 expression in Treg cells is impor-
tant for control of Th2 cell responses as demonstrated by the
dysregulated Th2 cell responses observed in mice that lackIRF4 in Foxp3+ Treg cells (Zheng et al., 2009). Many of the
IRF4-dependent genes are upregulated in TIGIT+ Treg cells
(Figure 2E), which is in line with the increased expression ofImmunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 571
Figure 2. Expression Profiling of TIGIT+ Treg Cells
(A and B) Heatmap of chemokine (receptor) and cytokine (receptor) (A) or transcription factor (B) genes that are differentially expressed (>1.5-fold) in CD4+
Foxp3+TIGIT+ and CD4+Foxp3+TIGIT Treg cells (duplicate samples are shown).
(C) Differential expression of a selection of genes from (B) was determined by quantification of mRNA in CD4+Foxp3+TIGIT+ and CD4+Foxp3+TIGIT Treg cells
by RT-PCR. Mean ± SD of at least three independent experiments is shown.
(D–F) Volcano plots comparing the p value versus fold-change for probes from TIGIT+ versus TIGIT Treg cells. Treg cell signatures generated from (D) CXCR3+
versus CXCR3 Treg cells, (E) WT versus IRF4 KO Treg cells, and (F) Treg cells from GFP-Foxp3 fusion protein reporter mice versus Foxp3-IRES-GFP mice are
highlighted in red (overexpressed) and green (underrepresented). p values form a chi-square test.
Genes and Probe IDs included in the signatures are listed in Table S2.
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TIGIT+ Treg Cells Suppress Proinflammatory ResponsesIrf4 by TIGIT+ Treg cells (Figure 2C). Finally, we found that TIGIT+
Treg cells share features with Treg cells from mice in which
Foxp3 is modified by an N-terminal fusion with GFP, leading to
modified interaction with Foxp3 cofactors (Figure 2F; Bettini
et al., 2012; Fontenot et al., 2005). In these mice the GFP fusion
altered the molecular characteristics of Foxp3, reducing its
interaction with HIF-1a and promoting interaction with IRF4,
modifying the Treg cell transcriptome and resulting in enhanced
suppression of Th2 and Th17 cell responses but weaker sup-
pression of Th1 cell responses (Bettini et al., 2012; Darce et al.,
2012). Overall, these data suggest that, rather than representing
a subset specialized to suppress a specific T effector lineage,572 Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc.TIGIT+ Treg cells express features of multiple effector and regu-
latory T cell subsets.
TIGIT+ Treg Cells Express a Gene Profile Indicative
of a Highly Suppressive Treg Cell Subset
Effector as well as regulatory T cell function is shaped by the
cytokine environment as well as engagement of costimulatory
ligands. We therefore examined the transcriptional profile of
TIGIT+ and TIGIT Treg cells for differential expression of mem-
brane receptors and detected a distinct pattern of costimulatory
molecule expression in TIGIT+ Treg cells. TIGIT+ Treg cells ex-
pressed higher amounts of the costimulatory molecule ICOS
Figure 3. TIGIT+ Treg Cells Express a Gene Profile Indicative of a Highly Suppressive Treg Cell Subset
(A) Heat map of surface receptor genes that are differentially expressed (>1.5-fold, duplicate samples) in CD4+Foxp3+TIGIT+ and CD4+Foxp3+TIGIT Treg cells.
(B and C) Quantitative RT-PCR (B, mean ± SEM) and flow cytometric (C) confirmation for a selection of genes from (A) and (D).
(D) Heatmap of differentially expressed genes involved in Treg cell differentiation and function.
(E) Volcano plot comparing the p value versus fold-change for probes from TIGIT+ versus TIGIT Treg cells. The canonical Treg cell signature is highlighted in red
(transcripts upregulated in Treg cells) and green (transcripts downregulated in Treg cells).
(F) Foxp3 protein expression was quantified by flow cytometry in mouse Foxp3 (Teff) or Foxp3+ (Treg) and human memory T cells (CD4+CD127+CD25med; Teff)
and Treg cells (CD4+CD127loCD25hi) (n = 9; *p < 0.05).
(G) Relative expression of the indicated genes in CD4+Foxp3+TIGIT+ and CD4+Foxp3+TIGIT Treg cells was determined by quantitative PCR (mean ± SEM).
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TIGIT+ Treg Cells Suppress Proinflammatory Responsesand had increased expression of a number of coinhibitory mole-
cules, such as CTLA-4, PD-1 (Pdcd1), Lymphocyte activation
gene 3 (Lag3), and T cell Immunoglobulin and Mucin 3 (Tim3,
Havcr2) (Figures 3A–3C and S2). Coinhibitory molecules such
as CTLA-4 and PD-1 not only serve as markers for T cell acti-
vation but also contribute to Treg cell stability and function(Francisco et al., 2009; Wing et al., 2008), indicating that TIGIT+
Treg cells might be better equipped for mediating suppression.
Indeed, TIGIT+ Treg cells expressed higher amounts of CTLA-
4, CD25, and GITR but showed no or only slight differences in
the expression of Lag3 (Figures 3C and 3G and S2). In mice,
CD39 and chemokine receptor 6 (CCR6) expression in TIGIT+Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 573
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TIGIT+ Treg Cells Suppress Proinflammatory ResponsesTreg cells is comparable to TIGIT Treg cells whereas human
TIGIT+ Treg cells upregulated expression of these markers (Fig-
ures 3C and S2B). When comparing TIGIT+ to TIGIT Treg cells,
the immunosuppressive cytokine IL-10 was primarily produced
by TIGIT+ Treg cells (Figure 3C). Furthermore, we found Treg-
cell-signature genes and mediators of the suppressive function
to also be differentially expressed in TIGIT+ versus TIGIT Treg
cells (Figures 3D–3G and S2). qPCR and flow cytometry analysis
showed TIGIT+ Treg cells to express higher amounts of Foxp3
than TIGIT Treg cells (Figures 3F and 3G). In addition, CD25
and Treg cell effector molecules, such as Granzyme B, IL-10,
and Fgl2, were also expressed in higher amounts in TIGIT+
Treg cells (Figures 3C, 3D, 3G, and S2A). TIGIT+ Treg cells there-
fore display a transcriptional profile that suggests an activated,
highly suppressive Treg cell subset.
TIGIT Ligation Induces the Treg Cell Effector
Molecule Fgl2
We next tested whether TIGIT ligation could directly induce
Treg cell effector molecules. Among these, IL-10 and Fgl2 stood
out as particularly interesting molecules because both were
highly expressed in TIGIT+ Treg cells (Figure 3G) and are able
to suppress proinflammatory responses (Chan et al., 2003;
Ku¨hn et al., 1993). To test whether expression of Fgl2 and
IL-10 could be induced through TIGIT, we isolated regulatory
T cells and stimulated them in vitro in the presence of an
agonistic TIGIT antibody (Ab). TIGIT ligation triggered a 2-fold
increase in Il10 gene expression by Treg cells in vitro. Similarly,
Fgl2 expression in Treg cells was increased in the presence
of agonistic TIGIT Ab, demonstrating that TIGIT signaling
induces Fgl2 transcription in TIGIT+ Treg cells (Figures 4A and
4B). We went on to determine whether TIGIT was also able
to induce Fgl2 and IL-10 in vivo. Our TIGIT Ab also acts agonis-
tically in vivo and does not affect Treg cell frequencies or com-
position (Figures S3A and S3B), so we tested whether treatment
of immunized mice with the Ab would result in induction of either
effector molecule. Cells were isolated 10 days after immuniza-
tion and restimulated for 2 days in vitro, and culture superna-
tants were analyzed for Fgl2 and IL-10. IL-10 could not be
detected in these cultures (not shown). However, Fgl2 was
increased in cell supernatants from Treg cells from anti-TIGIT-
treated mice (Figure 4C). TIGIT, therefore, induces Fgl2 in vitro
and in vivo.
We next addressed whether neutralizing IL-10 and Fgl2 would
abolish the difference in in vitro suppressive capacity of TIGIT+
and TIGIT Treg cells. In line with previous reports, blocking or
deletion of IL-10 had no effect on suppression by TIGIT+ or
TIGIT Treg cells in vitro (Figure 4D; Thornton and Shevach,
1998). Similarly, neutralizing or deleting Fgl2 had no effect on
the suppression by TIGIT Treg cells, which express only mini-
mal amounts of Fgl2 (Figures 4A and 4E). In contrast, after
neutralization or deletion of Fgl2, the suppressive activity of
TIGIT+ Treg cells was similar to that observed for TIGIT Treg
cells (Figure 4E), indicating that Fgl2 drives increased suppres-
sion by TIGIT+ Treg cells in vitro. In contrast, Fgl2 deficiency
had no effect on the TIGIT-mediated induction of Foxp3 or
IL-10 (Figures S3C and S3D). Therefore, TIGIT ligation triggers
secretion of Fgl2 by Treg cells, which enables them to act as
potent suppressors.574 Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc.To better understand how TIGIT induced Fgl2 expression,
we searched the genomic region of Fgl2 for binding sites of
transcription factors that showed differential expression in the
microarray analysis of TIGIT+ versus TIGIT Treg cells (Fig-
ure 2B). Fgl2was found to contain binding sites for the transcrip-
tion factor CEBPa, which was differentially expressed in TIGIT+
Treg cells. Quantitative PCR confirmed that CEBPa is highly
expressed in TIGIT+ but not TIGIT Treg cells (Figure 4F) and
that TIGIT engagement is able to upregulate Cebpa transcription
in Treg cells (Figure 4G). Chromatin immunoprecipitation (ChIP)-
PCR by an anti-CEBPa Ab together with primer pairs specific
for the Fgl2 genomic region confirmed that CEBPa binds to the
Fgl2 gene as predicted (Figure 4H). To further analyze whether
CEBPa can promote transcription of Fgl2, we overexpressed
CEBPa in nTreg cells and observed an increase in Fgl2 expres-
sion (Figure 4I). TIGITmight therefore promote Treg cell suppres-
sion by inducing CEBPa and thereby Fgl2 expression.
TIGIT+ Treg Cells Inhibit Th1 and Th17 Cell but Not Th2
Cell Differentiation
Fgl2 not only suppresses effector T cell proliferation, it also shifts
the cytokine profile toward a Th2 cell response as it inhibits Th1
cell responses while promoting Th2 cell polarization and induc-
tion of IL-10 and IL-4 (Chan et al., 2003; Shalev et al., 2008).
Furthermore, Fgl2 is important for Treg cell function in vivo as
shown by the fact that Fgl2-deficient Treg cells show impaired
control of effector T cell expansion in lymphopenic hosts (Fig-
ure S4A). Because TIGIT+ Treg cells produce high amounts
of Fgl2, we reasoned that they might differentially suppress
distinct T helper cell lineages. To test this, we cocultured naive
T cells and TIGIT and TIGIT+ Treg cells under differentiation
conditions for Th1, Th2, and Th17 cells and assessed expres-
sion of lineage-specific cytokines. TIGIT+ Treg cells showed
no difference in suppression of Th1 cell differentiation when
compared to TIGIT Treg cells as indicated by reduced expres-
sion of IFN-g (Figures 5A and S4B). Similarly, both subsets
potently suppressed expression of IL-17 by Th17 cells. However,
in contrast to TIGIT Treg cells, TIGIT+ Treg cells did not sup-
press differentiation of Th2 cells, as indicated by comparable
IL-4 production as in unsuppressed controls (Figures 5A and
S4B). This effect was dependent on Fgl2, as shown by the fact
that loss of Fgl2 in TIGIT+ Treg cells restored the ability to sup-
press Th2 cell differentiation, indicating that Fgl2 produced by
TIGIT+ Treg cells interferes with suppression of Th2 cell re-
sponses (Figures 5A and S4B). Although Fgl2 contributes to
suppression of effector T cell proliferation under Th1, Th2, and
Th17 cell conditions (Figure S4C), it does not contribute to
suppression of Th1 and Th17 cell cytokine production. It is,
however, needed to prevent suppression of the Th2 cytokine
IL-4. In line with these results, human effector T cells cultured
in the presence of TIGIT+ Treg cells were also inhibited in
Th1 and Th17 cell but not Th2 cell cytokine production
(Figure 5B).
TIGIT+ Treg Cells Inhibit Th1 and Th17 Cell but Not Th2
Cell Responses In Vivo
To test whether our in vitro results also translated into selective
suppression of Th1 and Th17 cell versus Th2 cell responses
in vivo, we transferred TIGIT+ and TIGIT OVA-specific OT-II
Figure 4. TIGIT Ligation Induces Fgl2 Expression
(A) Foxp3 (Teff) and Foxp3+ (Treg) cells were sorted from Foxp3-GFP.KI mice, stimulated with anti-CD3 and anti-CD28 in the presence of agonistic TIGIT Ab.
After 3 days RNA was extracted and Fgl2 and Il10 mRNA was quantified by quantitative RT-PCR.
(B) Ex vivo human memory T cells (CD4+CD127+CD25med) and Treg cells (CD4+CD127loCD25hi) were sorted gating into TIGIT+ and TIGIT. After isolation, cells
were cultured in the presence of agonistic anti-TIGIT or isotype control for 4 days. FGL2 expression was quantified by RT-PCR (n = 6; *p < 0.05).
(C) Mice were immunized s.c. with MOG35–55 peptide in CFA and treated with anti-TIGIT or isotype control antibody. On day 10 cells were restimulated with
MOG35-55 peptide for 48 hr. Fgl2 concentrations in the supernatants were determined by ELISA.
(D and E) CD4+CD25+TIGIT+ (closed bars) or CD4+CD25+TIGIT (open bars) Treg cells were sorted from WT, IL-10-deficient (D), or Fgl2-deficent (E) mice and
cocultured with CD25 effector T cells stimulated with anti-CD3 and APCs at a ratio of 1:8. Where indicated neutralizing anti-IL-10 (D) or anti-Fgl2 (E) Ab or the
respective isotype control Ab was added to the culture. Proliferation was measured after 72 hr by 3H-thymidine incorporation.
(F) CD4+Foxp3+TIGIT+ and CD4+Foxp3+TIGIT Treg cells were sorted from Foxp3-GFP.KI mice and mRNA for Cebpa was measured by RT-PCR.
(G) Cells were isolated and stimulated as in (A) and on day 3 Cebpa mRNA was examined by quantitative RT-PCR.
(H) ChIP assays were performed on P815 cells expressing TIGIT with anti-CEBPa antibody or an isotype control. The precipitated chromatin was analyzed by
quantitative PCR with primers specific for three promoter and four intragenic regions of the Fgl2 gene with predicted CEBPa binding sites. Signals are displayed
as percent of the total input chromatin.
(I) CD4+Foxp3+ Treg cells were sorted from Foxp3-GFP.KI mice and transfected with a CEBPa overexpression construct (CEBPa) or the empty vector as control
(control) and stimulated with anti-CD3/CD28 Dynabeads. Relative expression of Fgl2 mRNA was determined by RT-PCR 4 days later.
All panels represent mean ± SD.
Immunity
TIGIT+ Treg Cells Suppress Proinflammatory ResponsesTreg cells together with OT-II effector cells into WT recipients
and analyzed the ability of the different Treg cell subsets to
suppress Th1, Th17, and Th2 cell responses upon immunization.Under conditions that induce a Th1- and Th17-cell-dominated
response (OVA in CFA), TIGIT+ and TIGIT Treg cells were
equally capable of suppressing effector T cell expansion asImmunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 575
Figure 5. TIGIT+ Treg Cells Suppress Th1 and Th17 Cell but Not Th2 Cell Responses
(A) Naive effector T cells, WT Foxp3+TIGIT Treg cells, WT Foxp3+TIGIT+ Treg cells, and Fgl2/ Foxp3+TIGIT+ Treg cells were sorted and cocultured at a ratio of
1:10 under Th1, Th2, or Th17 cell polarizing conditions. After 3 days mRNA was measured by quantitative RT-PCR. On day 5 intracellular cytokines in CD45.1+ T
effector cells were determined by flow cytometry (values normalized to unsuppressed controls, mean ± SEM; *p < 0.05, **p < 0.001, paired Student’s t test).
(B) Human TIGIT+ and TIGIT Treg cells (CD4+CD25hiCD127) were sorted and cocultured with CFSE-labeled CD25-depleted CD4+ T effector cells. Gene
expression (qRT-PCR) and intracellular cytokines (flow cytometry) were measured on day 4 (mean ± SEM; n = 6).
(C–F) CD25 effector OT-II cells and CD25hi OT-II Treg cells (TIGIT, TIGIT+, or no Treg cell control) were transferred i.v. into WT recipients and mice were
immunized with OVA in CFA. Data shown as mean ± SEM.
(C and D) Expansion of Vb5+ OT-II T cells (C) and proliferation in response to OVA323-339 (D) were determined 10 days later.
(E and F) Intracellular cytokine levels were determined by flow cytometry (E) and cytokine concentration in the culture supernatants was determined by cytometric
bead array (F).
(G–I) CD25 effector OT-II cells and CD25hi OT-II Treg cells (TIGIT, TIGIT+, or no Treg cell control) were transferred i.v. into WT recipients. Mice were then
sensitized with OVA (i.p.) on days 0 and 7 and challenged with aerosolized OVA on days 14–17 to induce allergic airway inflammation. (G) Total numbers of Vb5+
OT-II cells in lungs, (H) intracellular cytokine levels from lung-infiltrating CD4+ T cells, and (I) total eosinophil numbers in bronchoalveolar lavage fluid were
determined by flow cytometry. Pooled data from two experiments are shown (mean ± SEM; n = 8).
Immunity
TIGIT+ Treg Cells Suppress Proinflammatory Responsesdetermined by the number of Vb5+ OT-II cells. In addition, in vivo
differentiation of Th1 and Th17 cells was suppressed equally
well by TIGIT+ and TIGIT Treg cells as judged by IFN-g and
IL-17 production (Figures 5C–5F). When mice were immunized
for induction of Th2-cell-mediated allergic airway inflammation,
TIGIT Treg cells were able to suppress the disease. In contrast,
TIGIT+ Treg cells failed to inhibit recruitment of antigen-specific
Vb5+ OT-II cells to the lung and production of Th2 cytokines
(IL-4 and IL-13) was significantly higher than in mice that had
received TIGIT Treg cells (Figures 5G and 5H). Consistent
with an increase in Th2 cells in the presence of TIGIT+ Treg cells,
we observed high numbers of eosinophils in the bronchoalveolar
lavage of these mice (Figure 5I). Taken together, these data indi-
cate that TIGIT+ Treg cells selectively suppress proinflammatory
Th1 and Th17 cell, but not Th2 cell, responses.576 Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc.Based on these results, wewanted to test whether TIGIT+ Treg
cells might shift effector T cell responses toward a Th2 cell
phenotype, if the system is not biased by immunization with
adjuvant, and therefore took advantage of the Rag-transfer
model of colitis (Izcue et al., 2008). To induce disease, congeni-
cally marked effector T cells were transferred into Rag1/
recipients, either alone or together with TIGIT+Foxp3+ or
TIGITFoxp3+ Treg cells. Mice that received the effector
T cells alone lost weight over time, whereas cotransfer of either
TIGIT+ or TIGIT Treg cells promoted disease suppression (Fig-
ure 6A). Despite the difference in suppressive capacity that we
observed in vitro, both Treg cell populations were able to
suppress the disease equally well. Cotransfer of either Treg
cell population prevented tissue inflammation, as indicated by
the histopathological colitis score (Figure 6B), and suppressed
Figure 6. TIGIT+ Treg Cells Suppress Proinflammatory Responses In Vivo
To induce colitis CD45RBhi effector T cells (CD45.1) were transferred into Rag1/ mice together with TIGIT+ or TIGIT Treg cells (CD45.2) or no Treg cells as
controls (Teff:Treg cell ratio was 4.4:1 for TIGIT+ Treg cells and 3.6:1 for TIGIT Treg cells).
(A and B) Mice were monitored for weight loss over 10 weeks and (B) total colitis scores were determined by histopathology.
(C–E) At 10 weeks after transfer, mesenteric LNs were harvested and (C) total number of infiltrating CD4+ T cells, (D) proportion of Foxp3+ Treg cells among CD4+
T cells, and (E) Foxp3 expression among the transferred Treg cell population (CD45.2+) were determined by flow cytometry.
(F) Mesenteric LN cells were restimulated in vitro with 0.5 mg/ml anti-CD3 for 3 days and cytokine secretion was determined by cytometric bead array in
supernatants.
(G and H) CD45RBhi effector T cells (CD45.1) and WT or Fgl2/ TIGIT+ or TIGIT Treg cells (CD45.2) were cotransferred into Rag1/ mice on day 1, which
were then immunized with OVA in alum on day 0 and 7. On day 14 (G) total number of CD4+CD45.1+ effector T cells and (H) frequencies of cytokine producing
cells upon restimulated with PMA+ionomycin were determined by flow cytometry.
*p < 0.05, **p < 0.01, ***p < 0.005; all panels show mean ± SD.
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TIGIT+ Treg Cells Suppress Proinflammatory Responsesthe expansion of effector T cells in vivo (Figure 6C). In addition,
TIGIT+ and TIGIT Treg cells displayed comparable ability to
expand and persist in vivo (Figures 6D and 6E). TIGIT+ as well
as TIGIT Treg cells were able to suppress proinflammatory cy-
tokines as shown by the fact that T cells from the mesenteric
lymph nodes (LNs) produced significantly lower amounts of
IFN-g and TNF-a than those from mice that did not receiveTreg cells (Figures 6F and S5). In contrast, TIGIT+ Treg cells
did not suppress or may have even increased the expression
of IL-10 and the Th2 cytokine IL-4 when compared to the control
group (no Treg cells) (Figure 6F). Intracellular cytokine staining
revealed that whereas IL-10 was produced by both effector
T cells and Treg cells, IL-4 was entirely produced by effector
T cells (Figure S5). Next, we tested whether the sparing of Th2Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 577
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TIGIT+ Treg Cells Suppress Proinflammatory Responsescells was also dependent on Fgl2 in vivo. To this end, effector
T cells and either WT or Fgl2-deficient Treg cells were cotrans-
ferred into Rag1-deficient mice, which were then immunized
and boosted with OVA in Alum on days 0 and 7. In line with our
in vitro results, Fgl2 contributed to suppression of T cell prolifer-
ation but was not required for inhibition of IFN-g secretion by
effector cells (Figures 6G and 6H). In contrast, the inability of
TIGIT+ Treg cells to suppress Th2 cell responses was again
dependent on Fgl2 (Figure 6H). TIGIT+ Treg cells therefore sup-
press proinflammatory responses in vivo, while sparing or pro-
moting Th2-like responses in an Fgl2-dependent manner.
DISCUSSION
In this study, we identified TIGIT+Foxp3+ T cells as a distinct Treg
cell subset that specifically suppresses proinflammatory Th1
and Th17 cell but not Th2 cell responses through the secretion
of Fgl2, which was induced by engagement of TIGIT. TIGIT+
Treg cells therefore shift the balance toward Th2 cell responses
by suppressing proinflammatory effector Th1 and Th17 cell
responses, but not Th2 cell responses. This is an example of
how a coinhibitory molecule can mediate selective inhibition of
certain effector responses while leaving others intact.
TIGIT was first described as an inhibitory molecule that
suppresses immune responses indirectly by regulating DC func-
tion. By interacting with its ligand CD155 on DCs, TIGIT was
shown to induce IL-10 and suppress IL-12 production in DCs
and thereby inhibit Th1 cell responses (Yu et al., 2009). In our
previous studies we showed that TIGIT also has T-cell-intrinsic
inhibitory effects (Joller et al., 2011). Because Treg cells are
the primary cell type that constitutively expresses TIGIT, we
suspect that many of the DC effects that have been observed
might be mediated by TIGIT+ Treg cells. In addition to TIGIT-
induced IL-10 produced by the DCs themselves, we propose
that increased amounts of IL-10 and Fgl2 produced by TIGIT+
Treg cells may also contribute to the generation of tolerogenic
DCs and thereby inhibit the generation of effector T cell re-
sponses. Although TIGIT-induced IL-10 was shown to suppress
both IL-12p35 and IL-12p40 (Yu et al., 2009), the effect of Fgl2
in suppressing these key differentiating cytokines has not been
evaluated. We propose that IL-10 and Fgl2 secreted by TIGIT+
Treg cells may act in concert to suppress both IL-12 and IL-23
production from activated DCs and thereby inhibit development
of both Th1 and Th17 cell responses.
It has become clear that Treg cells represent a very hetero-
geneous population that encompasses many specialized sub-
populations. Whereas Foxp3 is necessary to equip T cells with
basic Treg cell functions (Fontenot et al., 2005), additional fac-
tors are required for efficient suppression of effector T cell re-
sponses in vivo and for maintaining immune tolerance. Several
transcription factors have been identified that drive additional
programs in Treg cells to efficiently control certain classes of
effector T cells and immune responses in defined target tissues.
For instance, Treg cells that are specialized in controlling specific
effector T cell lineages coexpress lineage-specific transcription
factors from T helper cells, such as T-bet, IRF4, Stat3, or Bcl6
to fulfill their subset-specific inhibitory functions (Chaudhry
et al., 2009; Chung et al., 2011; Koch et al., 2009; Linterman
et al., 2011; Zheng et al., 2009). TIGIT+ Treg cells share features578 Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc.with several different Treg cell subsets and express more T-bet
and IRF4, as well as Th17-cell-specific transcription factors
such as RORa and RORg, than did TIGIT Treg cells. The fact
that TIGIT+ Treg cells express elevated amounts of IRF4 would
suggest that they are well equipped for suppression of Th2
cell responses because IRF4 deficiency in Foxp3+ T cells results
in spontaneous Th2 cell pathology (Zheng et al., 2009). However,
our data suggest that TIGIT+ Treg cells do not suppress Th2
cell responses but effectively inhibit proinflammatory Th1 and
Th17 cell responses. It should be noted that IRF4 is not only
expressed in Th2 cells but is also required for Th17 cell differen-
tiation. Although conditional deletion of IRF4 in Foxp3+ Treg cells
most prominently affects control of Th2 cell responses, these
mice also have slightly elevated amounts of IL-17 (Zheng et al.,
2009) and in settings in which the immune response is domi-
nated by Th17 effector cells, such as arthritis, diminished func-
tion of IRF4 in Treg cells results in impaired control of Th17 cell
responses (Darce et al., 2012). Although TIGIT+ Treg cells
seem to share the inability to suppress Th2 cell responses with
IRF4-deficient Treg cells, the fact that they potently suppress
Th17 cell responses distinguishes them from IRF4-deficient
Treg cells.
Our findings suggest that in addition to the lineage- and tissue-
specific transcription factors, coinhibitory molecules like TIGIT
also contribute to the functional specialization of Treg cells
by inducing a distinct set of suppressive mediators that can
selectively suppress certain classes of effector T cell responses.
Although we found that the specialized TIGIT+ and TIGIT Treg
cell subsets display a certain degree of plasticity, both popula-
tions are sufficiently stable to mediate differential TIGIT-depen-
dent biological effects in the in vivomodels of asthma and colitis,
which span a 3 or 10 week time period, respectively. In the case
of TIGIT+ Treg cells, expression of Fgl2 allows them to selectively
spare Th2 cell responses while maintaining efficient suppression
of Th1 and Th17 cell responses. Coinhibitory receptors might
therefore tailor the suppressive function of Foxp3+ Treg cells
to what is required in a specific inflammatory environment.
The expression pattern of these receptors and/or engagement
through their ligands in a particular tissue environment could
thereby alter the molecular signature of Treg cells and equip
them with specialized suppressive mechanisms that are tailored
for a specific tissue or type of inflammation.
Besides transcription factors, we now show that cell surface
molecules like TIGIT expressed on Foxp3+ Treg cells can differ-
entially suppress effector T cell responses, providing a target
by which defined subsets of Treg cells can be manipulated to
regulate immune and autoimmune responses.EXPERIMENTAL PROCEDURES
Animals
C57BL/6 (B6), B6.SJL-PtprcaPepcb/BoyJ (CD45.1), B6.129P2-Il10tm1Cgn/J
(Il10/), and B6.129S7-Rag1tm1Mom/J (Rag1/) mice were purchased from
the Jackson Laboratories. Foxp3-GFP.KI reporter mice (Bettelli et al., 2006),
Tigit/ mice (Levin et al., 2011), Tigit transgenic mice (Levin et al., 2011),
and Fgl2/mice (Shalev et al., 2008) have been previously described. Animals
were maintained in a conventional, pathogen-free facility at the Harvard
Institutes of Medicine (Boston, MA) and all experiments were carried out in
accordance with guidelines prescribed by the Institutional Animal Care and
Use Committee (IACUC) at Harvard Medical School.
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Peripheral venous blood was obtained from healthy control volunteers in
compliance with Institutional Review Board protocols at Yale University
School of Medicine. Total CD4+ T cells were isolated by negative selection
(CD4+ T cell isolation kit II, Miltenyi Biotec) and then sorted by flow cytometry.
Treg Cell Differentiation and Suppression Assays
Cells were cultured in DMEM supplemented with 10% (vol/vol) FCS, 50 mM
mercaptoethanol, 1 mM sodium pyruvate, nonessential amino acids, L-gluta-
mine, and 100 U/ml penicillin and 100 g/ml streptomycin. CD4+ T cells
from splenocytes and lymph node cells were isolated with anti-CD4 beads
(Miltenyi). For in vitro Treg cell differentiation, naive CD4+CD62L+CD44 cells
were sorted by flow cytometry and stimulated with plate bound anti-CD3
(145-2C11, 0.3 mg/ml) and anti-CD28 (PV-1, 2 mg/ml) in the presence of
2.5 ng/ml TGF-b (R&D). Foxp3 expression was assessed by flow cytometry
4 days later. For suppression assays, CD4+Foxp3 responder cells and CD4+
Foxp3+ Treg cells were flow sorted from Foxp3-GFP.KI reporter mice based
on GFP expression. CD4+Foxp3 (2 3 104/well) and CD4+Foxp3+ cells
were cultured in triplicate in the presence of soluble anti-CD3 (1 mg/ml) and
irradiated splenic APCs (1.2 3 105/well). After 48 hr cells were pulsed with
1 mCi [3H]thymidine for an additional 18 hr and harvested and [3H]thymidine
incorporation was analyzed to assess proliferation. Percentage of suppres-
sion = 100C.P.M. of well with the indicated ratio of effector: Treg cells /mean
C.P.M. of wells with CD4+Foxp3 effectors alone. Where indicated, anti-Fgl2
Ab (clone 6D9, 30 mg/ml, Abnova), anti-IL-10 Ab (clone JES5-16E3, Biolegend),
or an isotype control was added to the cultures. For human Treg cell suppres-
sion assays, CD25-depleted T cells were CFSE labeled and cocultured with
FACS-sorted Treg cells (TIGIT+ or TIGIT) at indicated ratios. Cells were
stimulated with Treg cell Inspector Beads (Miltenyi) at manufacturer’s recom-
mended concentration. At day 4, cells were stained with LIVE/DEAD Fixable
Dead Cell Stain Kit (Molecular Probes) to allow gating on viable cells and
proliferation was measured by CFSE dilution. Samples were analyzed by flow
cytometry.
Microarray
CD4+ T cells were prepurified from splenocytes and lymph node cells of naive
Foxp3-GFP.KI reporter mice via Dynal beads (Invitrogen), and CD4+Foxp3+
TIGIT+ and CD4+Foxp3+TIGIT cells were sorted by flow cytometry. CD4+
Foxp3+CXCR3+ and CD4+Foxp3+CXCR3 were similarly sorted from spleens
of Foxp3-GFP.KI mice. All cells were double-sorted for purity, the final
sort being directly into TRIzol (Invitrogen). RNA was extracted and used
to prepare probes for microarray analysis on the Affymetrix Mouse Gene1.0ST
platform, with ImmGen protocols (Heng and Painter, 2008). Microarray
data were analyzed with the GeneSpring 11 (Agilent; quantile normalization)
or GenePattern (RMA normalization) software. Genes of interest (fold change
> 1.5) were handpicked and two-way hierarchical clustering by Euclidean
distance metric was performed to generate heatmaps. Analysis of signature
genes within the TIGIT+/TIGIT comparison used previously determined
gene sets: a T cell activation/proliferation signature from in vivo activated
T cells (Hill et al., 2007); the canonical Treg/Tconv cell signature (Hill et al.,
2007); a gene set that distinguishes Treg cells which express the chimeric
GFP-Foxp3 fusion protein (Darce et al., 2012); and the IRF4-dependent sig-
nature in Treg cells (Zheng et al., 2009). p values form a chi-square test. The
genes and Probe IDs included in these signatures are listed in Table S2.
Flow Cytometry
Surface staining was performed for 20 min at 4C in PBS containing 0.1%
sodium azide and 0.5% BSA. For intracellular cytokine stainings, cells were
restimulated with phorbol 12-myristate 13-acetate (PMA, 50 ng/ml, Sigma),
ionomycin (1 mg/ml, Sigma), and GolgiStop (1 ml/1 ml, BD Biosciences) at
37C in 10% CO2 for 4 hr before staining was performed with the Cytofix/
Cytoperm kit (BD Biosciences). Intracellular staining for Foxp3 was performed
with the Foxp3 Staining Buffer Set (eBioscience). Antibodies were from Bio-
Legend except for anti-Foxp3 (eBioscience) and anti-Ki67 (BD Biosciences).
7AAD was purchased from BD Biosciences. Samples were acquired on a
FACSCalibur or LSRII flow cytometer (BD Biosciences) and analyzed with
the FlowJo software (Tree Star).Quantitative RT-PCR
RNAwas extracted with RNAeasy mini Kits (QIAGEN) and cDNAwas prepared
with the iScript cDNA synthesis kit (BioRad). Real-time PCR (RT-PCR) was
performed with Taqman probes and the 7500 Fast Real-Time PCR system
(Applied Biosystems). All samples were normalized to b-actin internal control.
In Vitro Antibody Treatment
CD4+Foxp3 effector T cells and CD4+Foxp3+ Treg cells were sorted from
Foxp3-GFP.KI reporter mice and stimulated at a density of 1 3 106/ml with
plate-bound anti-CD3 (145-2C11, 1 mg/ml), anti-CD28 (PV-1, 2 mg/ml), and
anti-TIGIT (4D4, 100 mg/ml) or isotype control antibody. RNA was isolated on
day 3. Antibodies to human TIGIT were kindly provided by ZymoGenetics
(a wholly owned subsidiary of Bristol-Myers Squibb). Cells were stimulated
with anti-CD3 (UCHT1, 1 mg/ml), anti-CD28 (28.2, 1 mg/ml), and IL-2 (10 U/ml)
in the presence of agonistic anti-TIGIT at 20 mg/ml or IgG isotype control. Gene
expression was assessed on day 4.
In Vivo Antibody Treatment
Mice were immunized s.c. with 200 ml of an emulsion containing 100 mg of
MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) in adjuvant oil (CFA) on
day 0 and treated i.p. with 100 mg of anti-TIGIT (clone 4D4) or isotype control
Ab (armenian hamster IgG) on days 0, 2, 4, 10, and 17. For antigen-specific
proliferation assays, spleens and lymph nodes were collected on day 10 and
2.5 3 106 cells/ml were restimulated with 50 mg/ml MOG35-55 peptide.
After 48 hr, Fgl2 concentrations in culture supernatants were determined by
ELISA (Biolegend).
ChIP-PCR and Overexpression
ChIP assays were performed on P815 cells expressing TIGIT with the
SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling) according to
the manufacturer’s instructions. Lysates were immunoprecipitated with
anti-C/EBPa antibody (8 mg; Santa Cruz Biotech, sc-61) or rabbit IgG isotype
control. Quantitative PCR reactions were performed with SYBR-Green on
ChIP-bound and input DNA. % input = 2% 3 2(CT 2% input sample – CT sample).
For CEBPa overexpression, CD4+Foxp3+ Treg cells were flow sorted from
Foxp3-GFP.KI reporter mice. 5 3 105 Treg cells/ml were stimulated with
Mouse T-Activator CD3/CD28 Dynabeads (Invitrogen) and transfected with
10 mg/ml of Cebpa cDNA in pCMV6-Kan/Neo or the empty vector, which
had been preincubated with FuGene 6 (Roche Diagnostics). RNA was ex-
tracted on day 4 with RNAeasy mini Kits (QIAGEN), samples were treated
with DNase (RNase-free DNase set, QIAGEN), and cDNA was prepared with
the iScript cDNA synthesis kit (BioRad). Cebpa overexpression was verified
by Taqman PCR.
Suppression of Th Cell Differentiation
For in vitro experiments, CD4+CD62L+ naive T cell from CD45.1 mice and
CD4+Foxp3+TIGIT+ or TIGIT Treg cells from Foxp3-GFP.KI mice (CD45.2)
were sorted and cultured at 105 Teff and 104 Treg cells/well. Cells were stim-
ulated with Mouse T-Activator CD3/CD28 Dynabeads (Invitrogen, 0.6 ml/well)
in the presence of polarizing cytokines (Th1: 4 ng/ml IL-12; Th2: 4 ng/ml
IL-4; Th17: 10 ng/ml IL-6, 2 ng/ml TGF-b; all cytokines from R&D). RNA was
extracted after 3 days and flow cytometric analysis was performed on day 5.
For in vivo experiments, 1–2 3 105 CD4+CD62L+CD25 sorted naive
effector T cell and 2.5–5 3 104 CD4+CD25+TIGIT+ or TIGIT Treg cells
(Teff:Treg cell 4:1) from OT-II mice were transferred i.v. into WT recipients
1 day before immunization. To elicit a Th1 and Th17 cell response, mice
were immunized with 10 mg OVA (Sigma) emulsified in CFA and spleens and
draining LNs were analyzed 10 days later. Allergic airway inflammation was
induced as described previously (Haworth et al., 2008; Rogerio et al., 2012).
In brief, mice were sensitized with 10 mg OVA in alum i.p. on days 0 and 7
and challenged with 6% (wt/vol) OVA aerosol for 25 min on days 14, 15, 16,
and 17. Cells from lung and bronchioalveolar lavage were analyzed directly
after challenge on day 17.
Alternatively, 7.53 105 CD4+CD62L+CD25 sorted naive effector T cell from
CD45.1 mice and 1.5 3 105 CD4+CD25+TIGIT+ or TIGIT Treg cells from WT
or Fgl2/ mice (CD45.2) transferred i.v. into Rag1/ recipients 1 day before
immunization. Mice were immunized with 10 mg OVA and 45 mg anti-IFN-g
(clone AN-18, Biolegend) in alum i.p. on days 0 and 7 and analyzed on day 14.Immunity 40, 569–581, April 17, 2014 ª2014 Elsevier Inc. 579
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CD4+CD45RBhi naive T cell from CD45.1 mice and CD4+Foxp3+ Treg cells
from Foxp3-GFP.KI mice were purified by cell sorting after enrichment for
CD4+ cells via anti-CD4 MACS beads. 8 3 105 CD4+CD45RBhi cells were
transferred i.v. into Rag1/ mice, either alone or with Treg cells (4:1 effector
T cell:Treg cell ratio) and mice were weighed weekly. At the time of sacrifice,
small and large intestine samples were fixed in neutral buffered formalin.
Routinely processed, paraffin-embedded tissue samples were stained
with hematoxylin and eosin (H&E). The presence and severity of colitis was
evaluated in a blinded manner and graded semiquantitatively from 0 to 3 for
the three following criteria: epithelial hyperplasia, leukocyte infiltration, and
the presence of crypt abscesses. Scores for each criterion were added to
give an overall inflammation score for each sample of 0–9.
Statistical Analysis
Statistical significance was assessed either by 2-tailed Student’s t test
(two groups) or by ANOVA for multiple groups with a post hoc Tukey’s test;
p values < 0.05were considered statistically significant. Statistical significance
values indicated as follows: *p < 0.05, **p < 0.01, and ***p < 0.005.
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